Ovarian Stimulation After Dehydroepiandrosterone Supplementation in Poor Ovarian Reserve
- Conditions
- Fertility-female
- Registration Number
- PACTR201911829230395
- Lead Sponsor
- faculty of medicine suez canal university
- Brief Summary
• There was no significant difference between the two groups’ demographic data. • There was no significant difference between the two groups’ baseline investigations and that indicated good randomization of cases and control. • The study group showed a statistically significant difference between the baseline investigations before taking DHEA supplementation and after 2 months of taking the DHEA supplementation, the mean basal FSH decreased from 12.16±0.94 to 10.19±1.22 and that was statistically significant. The mean AMH level increased from 0.81±0.14 to 0.99±0.17 but it failed to reach significance level. The basal E2 level decreased from 32.20±5.50 to 21.48±5.84 and that was statistically significant. The mean Antral follicular count by U/S increased from 1.68±0.63 to 2.72±0.89 and that was statistically significant. • The comparison between the study group baseline investigations after 2 months of DHEA supplementation and the control group showed that the mean basal FSH of the study group was 10.19±1.22 compared with 11.94±1.11 in the control group, and that was statistically significant. The mean AMH level in the study group was 0.99±0.17 compared to 0.844±0.141 in the control group showed an improvement in the study group but it failed to reach significance level. The basal E2 level in the study group was 21.48±5.84 compared with 32.92±6.49 in the control group and that was statistically significant. The mean Antral follicular count by U/S in the study group was 2.72±0.89 compared to 1.88±0.73 in the control group and that was statistically significant.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 50
1.Serum AMH <1.1 ng/ml
2.Serum FSH =10 mIU/L and =15 mIU/L on day 3 of cycle
3.Low antral follicle counts (AFC) = 4 on Day 3 of cycle
1.Patients exposed to cytotoxic or radiotherapy for pelvic malignancies.
2.Patients on herbal or hormonal therapy.
3.Patients with cystectomy or oophorectomy.
4.Cases contraindicated to be supplemented with DHEA
oChronic kidney diseases,
oChronic liver diseases,
oDiabetes,
oBreast or Uterine cancers,
oEndometriosis,
oFibroids,
oAdrenal gland hyperplasia,
oPsychological disorders like depression.
5.Hyperprolactinaemia.
6.Polycystic ovaries syndrome.
7.Severe male factor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effect of DHEA supplementation on ovarian reserve among females with poor ovarian reserve.
- Secondary Outcome Measures
Name Time Method To compare the outcomes of induction in both the study and the control groups, in which:<br>1.The number of mature follicles at time of ovulation.<br>2.The total dose of gonadotrophin stimulation needed for induction of ovulation.<br>3.The duration of ovarian stimulation.<br>4.E2 level at the day of hCG injection to assess the quantity and the quality of mature follicles.<br>